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Common variants in Alzheimer’s disease and risk
stratification by polygenic risk scores
Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together
with polygenetic risk stratification can contribute towards planning of feasible and efficient
preventive and curative clinical trials. We first perform a large genetic association study by
merging all available case-control datasets and by-proxy study results (discovery
n= 409,435 and validation size n= 58,190). Here, we add six variants associated with
Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants
in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal
a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4
carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the
amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk
of Alzheimer’s disease.
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Thus far, multiple loci associated with Alzheimer’s disease(AD) have been described next to causal mutations in twosubunits of γ-secretases, membrane-embedded aspartyl
complexes (PSEN1, PSEN2 genes), and the gene encoding one
target protein of these proteases, the amyloid precursor protein
gene (APP). The most prominent locus, APOE, was detected
almost 30 years ago using linkage techniques1. In addition,
genome-wide association studies (GWAS) of AD case-control
datasets and by-proxy AD case-control studies have identified 30
genomic loci that modify the risk of AD2–7. These signals account
for ~31% of the genetic variance of AD, leaving most of the
genetic risk as yet uncharacterized8. Further disentangling the
genetic constellation of common genetic variations underlying
AD can drive our biological insights of AD and can point toward
novel drug targets.
There are over 50 million people living with dementia and the
global cost of dementia is well above 1 trillion US$9. This means
there is a medical and economical urgency to efficiently test
interventions that are under development. Therefore, to increase
power and reduce duration of trials, pre-symptomatic patients
that are at high genetic risk of disease are increasingly
developed10. However, only carriers of causal mutations (APP,
PSEN1, and PSEN2) and the APOE ɛ4 allele are considered high
risk, while other common and rare genetic variants are ignored11.
Despite that, the combined effects of all currently known variants
in a polygenic risk score (PRS) is associated with the conversion
of mild cognitive impairment to AD12,13, the neuropathological
hallmarks of AD, age at onset (AAO) of disease14–17 and lifetime
risk of AD18.
In this work we aim to comprehend and expand the knowledge
of the genetic landscape underlying AD and provide additional
evidence that a PRS of variants can be a robust tool to select high
risk individuals with an earlier AAO. We first performed a meta-
GWAS integrating all currently published GWAS case-control
data, by-proxy case-control data, and the data from the Genome
Research at Fundació ACE (GR@ACE) study19. We confirm the
observed associations in a large independent replication study.
Then, we construct an update of the PRS and test whether the
effects of the PRS are influenced by diagnostic certainty, sex and
AAO groups. Lastly, we test whether the PRS could be used to
identify individuals at the highest odds of having AD and we
compared AAO of the AD cases. This study describes the iden-
tification of six variants associated with AD risk and provides an
extended PRS tool to select individuals at high risk of AD.
Results
Meta-GWAS of AD. We combined data from three AD GWASs:
the summary statistics calculated from the GR@ACE19 case-
control study (6331 AD cases and 6055 controls), the IGAP20
case-control study (up to 30,344 AD cases and 52,427 controls)
and the UKB AD-by-proxy case-control study21 (27,696 cases of
maternal AD with 260,980 controls, and 14,338 cases of paternal
AD with 245,941 controls, Fig. 1, Supplementary Data 1).
Although we observed inflation in the resulting summary statis-
tics (λ median= 1.08; see Supplementary Fig. 1d), it was not
driven by an un-modeled population structure (LD score
regression intercept= 1.036). The full details of the studies are
described in methods. After study-specific variant filtering and
quality-control procedures, we performed a fixed effects inverse-
variance-weighted meta-analysis22 on the summary statistics of
the three studies. Using this strategy, we identified a genome-wide
significant (GWS) association (p < 5 × 10−8) for 36 independent
genetic variants in 35 genomic regions (the APOE region contains
signals for ɛ4 and ɛ2). As a sensitivity analysis, we removed the
AD-by-proxy study and compared the resulted effect estimates
with and without this dataset. We found a high correlation
between the effect estimates from the case-control and by-proxy
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Fig. 1 Flow chart of analysis steps. Discovery meta-analysis in GR@ACE, IGAP stage 1+ 2 and UKBiobank followed by a replication in 16 independent
cohorts. The genome-wide significant signals found in meta-GWAS were used to perform a Polygenic Risk Score in a clinical and pathological AD dataset.
See Supplementary Methods to more information about the cohorts included and methods to the PRS generation. aExtended dataset (Moreno-Grau
et al.19), bStageI+ StageII (Kunkle et al.20), cBy proxy AD: Meta-analysis of maternal and paternal history of dementia (Marioni et al.21), dExtra and
independent GR@ACE dataset incorporated only for replication purposes, ePathologically confirmed AD cases, fAD cases diagnosed based on clinical
criteria, gControls participants aged 55 years and younger. N= Total of individuals within specified data.
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approaches for the significant loci (R2= 0.994, p= 8.1 × 10−37;
Supplementary Fig. 1e). Four genomic regions were not pre-
viously associated with AD (see Manhattan Plot, Fig. 2a).
Next, we aimed at replicating the associated loci in 16 cohorts
(19,087 AD cases and 39,101 controls in total), many of them
collected and analyzed by the European Alzheimer’s Disease
Biobank (JPND-EADB) project. We tested all variants with
suggestive association (p < 10−5) located within a 200 kb region
from the sentinel SNP. Overall, 384 variants were tested in the
replication datasets (Supplementary Data 2). Discovery and
replication were combined, and we identified associations in six
variants comprising five genomic loci annotated using FUMA23
(Table 1, Fig. 2b–f, Supplementary Fig. 2 and Supplementary
Results). In APP, we identified a common (MAF= 0.46) intronic
variant associated with a reduced risk of AD (rs2154481, OR= 0.95
[0.94–0.96], p= 1.39 × 10−11, Fig. 2f). In SHARPIN (SHANK
Associated RH Domain Interactor) gene, we found two missense
mutations (rs34173062/p.Ser17Phe and rs34674752/p.Pro294Ser)
that are in linkage equilibrium (R2= 1.3 × 10−6, D′= 0.014,
p= 0.96). Both missense variants increased AD risk (p.Ser17Phe,
MAF= 0.085, OR= 1.14 [1.10–1.18], p= 9.6 × 10−13 and p.
Pro294Ser, MAF= 0.052, OR= 1.13 [1.09–1.18], p= 1.0 × 10−9,
Fig. 2b). A variant close to the genes PRKD3 and NDUFAF7
(rs876461, MAF= 0.143) emerged as the most significant variant in
the region after the combined analysis (OR= 1.07 [1.05–1.09],
p= 1.3 × 10−9, Fig. 2c). In the 3’-UTR region of CHRNE
(Cholinergic Receptor Nicotinic Epsilon Subunit), rs72835061
(MAF= 0.085) was associated with a 1.09-fold increased risk of
AD (95% CI [1.06–1.11], p= 1.5 × 10−10, Fig. 2e). Our analysis also
strengthened the evidence of association with AD for three
additional genomic loci including an association with a variant in
PLCG2 (rs3935877, MAF= 0.13, OR= 0.92 [0.90–0.95], p= 6.9 ×
10−9, Fig. 2d), and confirmed another common variant in PLCG2, a
stop gain mutation in IL-34 and a variant near HS3ST1 (Table 1,
Supplementary Fig. 3 and Supplementary Data 2, 3). We were not
able to replicate two loci (ELK2AP and SPPL2A regions) that
showed suggestive association with AD (p < 1 × 10−7 in discovery).
Polygenic risk scores. In order to assess the robustness and
combined effect of the genetic landscape of AD (Fig. 3, Sup-
plementary Data 4), we constructed a weighted PRS based on
the 39 genetic variants (excluding APOE genotypes) that
showed GWS evidence of association with AD (see Methods,
Fig. 4 and Supplementary Data 5). We tested if the association
of the PRS with AD is independent of clinically important
factors that are considered in the selection of individuals for
clinical trials. First, we showed that the association of the PRS
with clinically diagnosed AD cases is similar to the association
with pathologically confirmed AD (OR= 1.30 vs. 1.38, per 1-SD
increase in the PRS). In this setting, adding variants below the
GWS threshold did not lead to a more significant association of
the PRS with AD (Fig. 4a). Next, we tested whether the PRS was
associated with AD in the presence of concomitant brain
pathologies (besides AD). Among our autopsy-confirmed AD
patients (n= 332), 84% had at least one concomitant pathology,
and the PRS was associated with AD in the presence of all tested
concomitant pathologies (Fig. 4b). Moreover, the patients often
had more than one concomitant pathology (48.8%), but no
difference was observed in the effect estimate of the PRS when
more than one pathology was present (Fig. 4b). Last, we
investigated the effect of sex and AAO (Fig. 4c). Our analysis
revealed that the effect of the PRS was the same in both sexes
(Fig. 4c) and was consistent with both early-onset (onset before
65 years; OR= 1.58, 95% CI [1.22–2.05], p= 5.8 × 10−4) as well
as with late-onset AD (onset later than 85 years; OR= 1.29, 95%
CI [1.10–1.51], p= 1.5 × 10−3).
PRSs has the potential to early identify subjects at risk of
complex diseases24. To identify people at the highest genetic






Fig. 2 GWAS meta-analysis for AD risk (N= 467,623). a Manhattan plot of overall meta-analysis for genome-wide association in Alzheimer’s disease
highlighting in pink the loci associated with AD in this study (PRKD3/NDUFAF7, SHARPIN, CHRNE, PLCG2, and APP). b–f Locus plots for the signals
associated with AD in overall meta-analysis results.
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PRS in the large GR@ACE dataset. The PRS was associated with a
1.27-fold (95% CI [1.23–1.32]) increased risk for every standard
deviation increase in the PRS (p= 7.3 × 10−39) and with a
gradual risk increase when we stratified the dataset into 2%
percentiles of the PRS (Fig. 5a, Supplementary Data 6). Next, we
stratified the dataset in APOE genotype risk groups. The PRS
percentiles were associated with AD within the APOE genotype
groups (Fig. 5b, Supplementary Data 7). Finally, we compared the
risk extremes and found a 16.2-fold (95% CI [8.84–29.5],
p= 1.5 × 10−19) increased risk for the highest-PRS group (APOE
ɛ4ɛ4) compared with the lowest-PRS group (APOE ɛ2ɛ2/ɛ2ɛ3;
Supplementary Data 8). When we compared the median AAO in
AD patients in these extreme risk groups we found a 9-year
difference in the median age (pWilcoxon= 1.7 × 10−6) (Fig. 5c).
Lastly, we studied the effects on AAO of the PRS in the APOE
genotype groups. The PRS differentiated AAO only within APOE
ɛ4 carriers. In APOE ɛ4 heterozygotes the PRS determined a 4-
year difference in median AAO and in APOE ɛ4 homozygotes
(pWilcoxon= 6.9 × 10−5), where the PRS determined a median
AAO difference of 5.5 years (pWilcoxon= 4.6 × 10−5). For the
selection of high-risk individuals, it is important to note that we
found no difference in the odds and AAO for AD for APOE ɛ4
heterozygotes with the highest PRS compared to APOE ɛ4
homozygotes with the lowest PRS. The Cox regression also
showed an impact of APOE on AAO, mainly on APOE ε4ε4
(significant APOE-PRS interaction (p= 0.021), Fig. 5d, Supple-
mentary Data 9).
Discussion
This work adds on the ongoing global effort to identify genetic
variants associated with AD (Fig. 3). In the present work, we
reported on the largest GWAS for AD risk to date, comprising
genetic information of 467,623 individuals of European ancestry.
We identified six variants that were not previously associated with
the risk of AD and constructed a robust PRS for AD demon-
strating its potential value for selecting subjects at risk of AD,
especially within APOE ɛ4 carriers. This PRS was based on
European ancestries and may or may not generalize to other
ancestries. Validation in other populations will be required. We
also acknowledge that controls included in GR@ACE are younger
than cases and some of the controls might still develop AD later
in life. This fact does not invalidate the analysis although reported
estimates must be considered conservative. The differences in risk
and AAO determined by the PRS of AD are relevant for design
clinical trials that over-represent APOE ε4 carriers, as APOE ε4
heterozygous with highest-PRS values have a similar risk and
AAO to APOE ɛ4 homozygotes (Fig. 5b). These represents ~1%
of our control population, which is the same percentage as all
APOE ε4 homozygotes. A trial that aims to include APOE ɛ4
homozygotes, could consider widening the selection criteria and
in this way hasten the enrollment process. Also, our PRS could
aid at the interpretation of the results of clinical trials, as it
determines a relevant proportion of the AAO, which could either
mimic or obscure a treatment effect.
The most interesting finding from our GWAS is the discovery
of a common protective (MAF (C-allele)= 0.483) intronic variant
in the APP gene. Our results directly support APP production or
processing as a causal pathway not only in familial AD but in
common sporadic AD. The SNP is in a DNase hypersensitive area
of 295 bp (chr21:27473781-27474075) possibly involved in the
transcriptional regulation of the APP gene. rs2154481 is an eQTL
for the APP mRNA and an antisense transcript of the APP gene
named AP001439.2 in public eQTL databases25 (Supplementary
Fig. 4). Functional evidence supports a modified APP
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(including rs2154481) increased the TFCP2 transcription factor
avidity to its binding site and increased the enhancer activity of
this specific intronic region26. Based on this evidence, we can
postulate that a life-long slightly higher APP gene expression
protects the brain from AD insults. Still, this seems counter-
intuitive as duplications of the gene lead to early-onset AD27. A
U-shaped effect, or hormesis effect of APP might help explain our
observations and it might also fit the accelerated cognitive dete-
rioration observed in AD patients treated with beta-secretase
inhibitors28,29 as these reduce beta-amyloid in their brain. An
alternative hypothesis is that mechanisms underlying the variant
are related to the overexpression of protective fragments of the
APP protein30. Disentangling the molecular mechanism of our
finding will help refine and steer the amyloid hypothesis.
Additionally, other three variants identified are altering protein
sequence or affecting regulatory motifs. Two independent mis-
sense mutations in SHARPIN increased the AD risk. SHARPIN
was previously proposed as an AD candidate gene31,32, and
functional analysis of a rare missense variant (NM_030974.3:p.
Gly186Arg) resulted in the aberrant cellular localization of the
variant protein and attenuated the activation of NF-κB, a central
mediator of inflammatory and immune responses. Functional
analysis of the two identified missense variants will show if the
effect on immune reaction in AD is similar. The variant located in
the CHRNE which encodes a subunit of the cholinergic receptor
(AChR) is a strong modulator of CHRNE expression. The same
allele that increases AD risk increases the expression in the brain
and other tissues according to GTEx (p= 2.1 × 10−13) (Supple-
mentary Fig. 5). The detection of a potential hypermorph allele
linked to AD risk and affecting cholinergic function could rein-
troduce this neurotransmitter pathway into the search for pre-
ventative strategies. Further functional studies are needed to
consolidate this hypothesis.
Altogether, we described six additional loci associated with
sporadic AD. These signals reinforce that AD is a complex disease
in which amyloid processing and immune response play key
roles. We add to the growing body of evidence that the polygenic
scores of all genetic loci to date, in combination with APOE
genotypes, are robust tools that are associated with AD and its
AAO. These properties make PRS promising in selecting indivi-
duals at risk to apply preventative therapeutic strategies.
Methods
Data. Participants in this study were obtained from multiple sources, including raw
data from case-control samples collected by GR@ACE/DEGESCO, summary sta-
tistics data from the case-control samples in the IGAP and the summary statistics
of AD-by-proxy phenotype from the UK Biobank. An additional case-control
samples from 16 independent cohorts (19,087 AD cases and 39,101 controls) was
used for replication, largely collected and analyzed by the European Alzheimer’s
Disease Biobank (JPND-EADB) project. Full descriptions of the samples and their
respective phenotyping and genotyping procedures are provided in the Supple-
mentary Methods.
GR@ACE. The GR@ACE study19 recruited AD patients from Fundació ACE,
Institut Català de Neurociències Aplicades (Catalonia, Spain), and control indivi-
duals from three centers: Fundació ACE (Barcelona, Spain), Valme University
Hospital (Seville, Spain), and the Spanish National DNA Bank–Carlos III (Uni-
versity of Salamanca, Spain) (http://www.bancoadn.org). Additional cases and
controls were obtained from dementia cohorts included in the Dementia Genetics
Spanish Consortium (DEGESCO)33. At all sites, AD diagnosis was established by a
multidisciplinary working group—including neurologists, neuropsychologists, and
social workers—according to the DSM-IV criteria for dementia and the National
Institute on Aging and Alzheimer’s Association’s (NIA–AA) 2011 guidelines for
diagnosing AD. In our study, we considered as AD cases any individuals with
dementia diagnosed with probable or possible AD at any point in their clinical
course. For further details on the contribution of the sites, see Supplementary
Data 10. Written informed consent was obtained from all the participants. The
ethics and scientific committees have approved this research protocol (Acta 25/
2016, Ethics Committee H., Clinic I Provincial, Barcelona, Spain).
Genotyping, quality control, and imputation. DNA was extracted from
peripheral blood according to standard procedures using the Chemagic system
(Perkin Elmer). Samples reaching DNA concentrations of >10 ng/μl and presenting
high integrity were included for genotyping. Cases and controls were randomized
across sample plates to avoid batch effects.
Genotyping was conducted using the Axiom 815K Spanish biobank array
(Thermo Fisher) at the Spanish National Center for Genotyping (CeGEN, Santiago
de Compostela, Spain). The genotyping array not only is an adaptation of the

















































































































































Gene Culprit gene found
Gene Culprit gene not found
Fig. 3 Genetic landscape for Alzheimer’s disease. This figure shows the history of genetic discoveries in AD research over the past 30 years. This figure
was constructed to our best knowledge of literature, but is not a systematic review of literature. For common variants, we selected only signals firmly
replicated in large meta-GWAS (Lambert et al.3, Kunkle et al.20, Jun et al.43, Sims et al.7, Jansen et al.38 and present study). For rare variants, we only
selected those variants widely replicated excluding those loci presenting conflicting results. Abbreviations and more information about the genes can be
found in Supplementary Data 4. The risk alleles associated with AD were represented in orange and the protective alleles in blue. GWAS Genome-Wide
Association Study, OR odds ratio.
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variations observed in the Spanish population. The DNA samples were genotyped
according to the manufacturer’s instructions (Axiom™ 2.0 Assay Manual
Workflow). The Axiom 2.0 assay interrogates biallelic SNPs and simple indels in a
single-assay workflow. Starting with 200 ng of genomic DNA, the samples were
processed through a manual target preparation protocol, followed by automated
processing of the array plates in the GeneTitan Multi-Channel (MC) instrument.
Target preparation involved DNA amplification, fragmentation, purification, and
resuspension of the target in a hybridization cocktail. The hyb-ready targets were
then transferred to the GeneTitan MC instrument for automated, hands-free
processing, including hybridization, staining, washing, and imaging. The CEL files
were generated using the GeneTitan MC instrument. Quality control (QC) was
performed for samples and plates using the Affymetrix power tool (APT)
1.15.0 software following the Axiom data analysis workflow. The sample quality
was determined based on the resolution of AT and GC channels in a group of non-
polymorphic SNPs (resolution > 0.82). Samples with a call rate greater than 97%
and plates with an average call rate above 98.5% were included for final SNP
calling. The samples were jointly called. Markers passing all the QC tests were used
in downstream analysis (NSNPs= 729,868; 95.4%) using the SNPolisher R package
(Thermo Fisher). To assess the sample genotyping concordance, we intentionally
resampled 200 samples and determined a concordance rate of 99.5%.
We also conducted previously described standard QC prior to imputation19. In
brief, individual QC includes genotype call rates >97%, sex checks, and no excess
heterozygosity; we removed population outliers as well (European cluster of 1000
Genomes). We included variants with a call rate of >95%, with a minor allele
frequency (MAF) of >0.01, in Hardy–Weinberg equilibrium (p < 1 × 10−4 in




Fig. 4 Polygenic risk scores for AD. a The 39-SNP PRS association with clinical (OR= 1.30, 95% CI [1.18–1.44], p= 1.1 × 10−7) and pathologically confirmed
AD cases (OR= 1.38, per 1-SD increase in the PRS, 95% CI [1.21–1.58], p= 1.5 × 10−6) from EADB–F.ACE/BBB dataset. b PRS association with AD in the
presence of concomitant brain pathologies (besides AD). c PRS association with AD stratified by sex and AAO. A similar association of the PRS with AD was
found in both sexes (ORmales= 1.33, [1.13–1.56], p= 5.8 × 10−4 vs. ORfemales= 1.32, [1.19–1.47], p= 2.5 × 10−7). In (a–c) data are presented as Odds Ratio
per 1-SD increase in PRS (95% CI). The generated PRS was validated using logistic regression adjusted by four principal components.
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(Supplementary Data 11, Supplementary Fig. 1). Imputation was carried out using
the Haplotype reference consortium34 (HRC, full panel) and the 1000 Genomes
reference panel35 (for indels only) on the Michigan Imputation Server (https://
imputationserver.sph.umich.edu). Rare variants (MAF < 0.001) and variants with
low imputation quality (R2 < 0.30) were excluded. Logistic regression models,
adjusted for the first four ancestry principal components19, were fitted using Plink
(v2.00a). Population-based controls were used; therefore, age was not included as a
covariate. Age and gender statistically behave like phenotype proxies (for AD status
in this case). Therefore, adjusting for co-variation with age and gender could result
in an over-adjustment of GWAS results. After QC steps, we included 6,331 AD
cases and 6,055 control individuals and tested 14,542,816 genetic variants for
association with AD.
IGAP summary statistics. The GWAS summary results from the IGAP were
downloaded from the National Institute on Aging Genetics of Alzheimer’s Disease
Data Storage Site (NIAGADS, https://www.niagads.org/)20. Details on data gen-
eration and analyses by the IGAP have been previously described20. In brief, the
IGAP is a large study based upon genome-wide association using individuals of
European ancestry. Stage 1 of the IGAP comprises 21,982 AD cases and 41,944
cognitively normal controls from four consortia: the Alzheimer Disease Genetics
Consortium (ADGC), the European Alzheimer’s Disease Initiative (EADI), the
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium, and the Genetic and Environmental Risk in AD/Defining Genetic,
Polygenic, and Environmental Risk for Alzheimer’s Disease (GERAD/PERADES)
Consortium. Summary statistics are available for 11,480,632 variants, both geno-
typed and imputed (1000 Genomes phase 1, v3). In Stage 2, 11,632 SNPs were
genotyped in an independent set of 8362 AD cases and 10,483 controls.
UK Biobank summary statistics. UK Biobank data—including health, cognitive, and
genetic data—was collected on over 500000 individuals aged 37–73 years from
across Great Britain (England, Wales, and Scotland) at the study baseline
(2006–2010) (http://www.ukbiobank.ac.uk)36. Several groups have demonstrated
the utility of self-report of parental history of AD for case ascertainment in GWAS
(proxy–AD approach)21,37,38. For this study, we used the published summary
statistics of Marioni et al.21. They included, after stringent QC, 314,278 unrelated
individuals for whom AD information was available on at least one parent in the
UK Biobank (https://datashare.is.ed.ac.uk/handle/10283/3364). In brief, the 27,696
participants whose mothers had dementia (maternal cases) were compared with
the 260,980 participants whose mothers did not have dementia. Likewise, the
14,338 participants whose fathers had dementia (paternal cases) were compared
with the 245,941 participants whose fathers did not have dementia21. The phe-
notype of the parents is independent, and therefore, the estimates could be meta-
analyzed. After analysis, the effect estimates were made comparable to a case-
control setting. Further information on the transformation of the effect sizes can be
found elsewhere21,39. The data available comprises summary statistics of 7,794,553
SNPs imputed to the HRC reference panel (full panel).
Meta-GWAS of AD. After study-specific variant filtering and quality-control
procedures, we performed a fixed effects inverse-variance–weighted meta-
analysis22 on the discovery and follow-up stages (Supplementary Data 1 and
Supplementary Data 12). To determine the lead SNPs (those with the strongest
association per genomic region), we performed clumping on SNPs with a GWS p
value (p < 5 × 10−8) (Plink v1.90, maximal linkage disequilibrium (LD) with R2 <
0.001 and physical distance 250 Kb). In the APOE region, we only considered the
APOE ɛ4 (rs429358) and APOE ɛ2 (rs7412) SNPs40. LD information was calculated
using the GR@ACE imputed genotypes as a reference. Polygenicity and con-
founding biases, such as cryptic relatedness and population stratification, can yield
an inflated distribution of test statistics in GWAS. To distinguish between inflation
from a true polygenic signal and bias we quantified the contribution of each by
examining the relationship between test statistics and linkage disequilibrium (LD)
using the LD Score regression intercept (LDSC software41). Chromosomal regions





Fig. 5 Polygenic Risk Scores APOE stratification for AD in n= 12,386 biologically independent samples from GR@ACE/DEGESCO. a The AD risk of PRS
groups compared to those with the 2% lowest risk. The 2% highest risk had a 3.0-fold (95% CI [2.12–4.18], p= 3.2 × 10−10) increased risk compared with
those with the 2% lowest risk. No interaction was found between the PRS and APOE genotypes (p value= 0.76). b The AD risk stratified by PRS and APOE
risk groups compared to the lowest risk group (OR 95% CI). Association was found between highest and lowest-PRS percentiles within the APOE genotype
groups: ɛ2ɛ2/ɛ2ɛ3 carriers (OR= 2.48 [1.51–4.08], p= 3.4 × 10−4), ɛ3ɛ3 carriers (OR= 2.67 [1.93–3.69], p= 3.5 × 10−9), ɛ2ɛ4/ɛ3ɛ4 carriers (OR= 2.47
[1.67–3.66], p= 6.8 × 10−6), and ɛ4ɛ4 carriers (OR= 2.02 [1.05–3.85], p= 3.4 × 10−2). Comparisons of the highest and lowest-PRS percentiles with
respect to the APOE genotype groups: a difference was found between highest ɛ2ɛ2/ɛ2ɛ3 carriers vs. lowest ɛ3ɛ3 carriers (OR= 0.51 [0.34–0.75],
p= 7.8 × 10−4), but not between highest ɛ3ɛ3 carriers vs. lowest ɛ2ɛ4/ɛ3ɛ4 carriers (OR= 1.17 [0.82–1.66], p= 0.40) and highest ɛ2ɛ4/ɛ3ɛ4 carriers vs.
lowest ɛ4ɛ4 carriers (OR= 0.89 [0.52–1.53], p= 0.68). c The AAO of AD stratified by PRS and APOE risk groups. No difference in odds for AD was found
between the PRS percentiles with AAO in APOE ɛ2ɛ2/ɛ2ɛ3 (lowest= 82 years, highest= 83 years, pWilcoxon= 0.39) and APOE ɛ3ɛ3 (lowest= 82 years,
highest= 81 years, p= 0.16). However, a 4-year difference was found between APOE ɛ4 heterozygotes (pWilcoxon= 6.9 × 10−5, 81 years compared with 77
years) and 5.5 years difference (pWilcoxon= 4.6 × 10−5, 78.5 years compared with 73 years) in APOE ɛ4 homozygotes. Data are represented as boxplots as
described in the manual of ggplot2 package in R. a–c Logistic regression models adjusted for four population ancestry components were used as statistical
test. d Cox regression model on AAO. The determinants are the PRS and the APOE categories, a PRS*APOE interaction term and population substructure as
covariates. The curve shows the probability a case in one of the eight groups has developed AD by a certain age (x-axis).
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et al.3, Kunkle et al.42, and Jansen et al.38). We tested all variants with suggestive
association (p < 10−5) located in proximity (200 kb) of genomic regions selected for
follow-up to allow for the potential refinement of the top associated variant.
Conditional analyses were performed in regions where multiple variants were
associated with AD using logistic regression models, adjusting for the genetic
variants in the region (Supplementary Data 13, 14).
Regional plots were generated with a mixture of homemade Python (v2.7) and
R (v3.6.0) scripts. Briefly, given an input variant, we calculated the LD between the
input variant and all the surrounding variants within a window of length defined
by the user. The LD was calculated in the 1000 Genomes samples of European
ancestry. We used gene positions from RefSeq (release 93); in the case of multiple
gene models for a given gene, we reported the model with the largest number of
exons. We used recombination rates from HapMap II and chromatin states from
ENCODE/Broad (15 states were grouped to highlight the predicted functional
elements). As a reference genome, we used GRCh37. Quantile–quantile plots,
Manhattan plots, and the exploration of genomic inflation factors were performed
using the R package qqman.
Polygenic risk scores. We calculated a weighted individual PRS based on the 39
genetic variants that showed GWS evidence of association with AD in the present
study, excluding APOE to check the impact of PRS modulating APOE risk (Table 1
and Supplementary Data 3). The selected variants were directly genotyped or
imputed with high quality (median imputation score R²= 0.93). The PRSs were
generated by multiplying the genotype dosage of each risk allele for each variant by
its respective weight and then summing across all variants. We weighted this by the
effect size from previous IGAP studies [Kunkle et al.42 (36 variants), Sims et al.7 (2
variants), Jun et al.43 (MAPT locus), Supplementary Data 5]. The generated PRS
was validated using logistic regression adjusted by four principal components in a
sample of 676 AD cases diagnosed based on clinical criteria and 332 pathologically
confirmed AD cases from the European Alzheimer’s Disease Biobank–Fundació
ACE/Barcelona Brain Bank dataset (EADB–F.ACE/BBB, Supplementary Infor-
mation). This dataset was not used in prior genetic studies. In this dataset, all
pathologically confirmed cases were scored for the presence or absence of con-
comitant pathologies. In all analyses, we compared the AD patients to the same
control dataset (n= 1386). We performed analyses to test the robustness of the
PRS. We tested the effect of adding variants below the genome-wide significance
threshold using a pruning and thresholding approach. For this, we used the
summary statistics of the IGAP42 study, and we selected independent variants
using the clump_data() function from the TwoSampleMR package (v0.4.25). We
used strict settings for clumping (R2= 0.001 and window= 1MB) and increasing p
value thresholds (>1 × 10−7, >1 × 10−6, >1 × 10−5, >1 × 10−4, >1 × 10−3, and >1 ×
10−2). We tested the association of the results with clinically diagnosed and
pathologically confirmed AD patients. To evaluate the effect of diagnostic certainty,
we tested whether the PRS was different between the two patient groups. For the
PRS with 39 GWS variants, we tested whether the PRS had sex-specific effects,
whether it resulted in different age-of-onset groups of AD, and the effect of the PRS
in the presence of concomitant brain pathologies.
Risk stratification of the validated PRSs. We searched for the groups at the
highest risk of AD in the GR@ACE dataset (6331 AD cases and 6055 controls). We
stratified the population into PRS percentiles, taking into account survival bias
anticipated at old age18. To eliminate selection bias, we calculated the boundaries of
the percentiles in the control participants aged 55 years and younger (n= 3546).
Based on the boundaries from this population, the rest of the controls and all AD
cases were then assigned into their appropriate percentiles. We first explored risk
stratification using only the PRSs. For this, we split the PRSs into 50 groups (2
percentiles) and compared all groups with that which had the lowest PRS. Second,
we explored risk stratification considering both the APOE genotypes and the PRSs.
The APOE genotypes were pooled in the analyses as APOE ɛ2ɛ2/ɛ2ɛ3 (n= 998,
split into 7 PRS groups), APOE ɛ3ɛ3 (n= 7611, split into 25 PRS groups), APOE
ɛ2ɛ4/ɛ3ɛ4 (n= 3399, split into 15 PRS groups), and APOE ɛ4ɛ4 (n= 382, split into
3 PRS groups). We studied the effect of PRS across groups of individuals stratified
by the APOE genotypes with the lowest-PRS group (APOE as the reference group
using logistic regression models adjusted for four population ancestry
components). Finally, we compared the median AAO using a Wilcoxon test.
We implemented a Cox regression model on AAO in the GR@ACE/DEGESCO
dataset case-only adjusted for covariates as APOE group, the interaction between
the PRS and APOE and four population ancestry components. All analyses were
done in R (v3.4.2).
Functional annotation. We used Functional Mapping and Annotation of Genome-
Wide Association Studies23 (FUMA, v1.3.4c) to interpret SNP-trait associations
(see Supplementary Methods and Supplementary Data 15–18). FUMA is an online
platform that annotates GWAS findings and prioritizes the most likely causal SNPs
and genes using information from 18 biological data repositories and tools. As
input, we used the summary statistics of our meta-GWAS. Gene prioritization is
based on a combination of positional mapping, expression quantitative trait loci
(eQTL) mapping, and chromatin interaction mapping. Functional annotation was
performed by applying a methodology similar to that described by Jansen et al.38.
We referred to the original publication for details on the methods and repositories
of FUMA23.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The discovery summary statistics of this study are publicly available in Fundació ACE
server [https://fundacioace-my.sharepoint.com/:u:/g/personal/iderojas_fundacioace_org/
EaTwlPg9cRJHn7Kos4h39OUBaxajsjJHL_C110fC89bc8w?e=ZdcEUy].
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